Journal of Clinical Oncology · 2006 · 10 citations · 0 references
MedicineOncologySurgeryOncologic SurgerySurgical OncologySurvival AnalysisCancer MortalityCancer StagingCancer Survival AnalysisDiabetes MellitusPancreatic SurgeryPrognostic AssessmentCox RegressionHistologic Tumor ClassificationOverall MortalityPancreatic Adenocarcinoma SurgeryPancreatic Cancer MortalityPancreatic Cancer ResectionPrognostic Factors AnalysisTumor Margin Status
4098 Background: Pancreatic cancer is the fourth leading cause of cancer mortality in the United States. Determining modifiable prognostic factors may be a key step in improving outcomes of these patients with overall poor survival. Pancreatic adenocarcinoma is often associated with diabetes. Our aim is to determine whether diabetes worsens disease specific mortality in resectable pancreatic cancer patients. Methods: In this study, we reviewed 298 patients with resected pancreatic adenocarcinoma in our surgical database at MD Anderson Cancer Center between August 1992 and July 2003. Patients were classified into diabetics (N = 87) (defined as those carrying the diagnosis of diabetes (DM) at time of presentation or on long term therapy for DM) and nondiabetics (N = 211). Univariate (log-rank) and Multivariate (Cox Regression) analyses were performed. Results: Compared to nondiabetics, patients with DM had a poorer overall survival with a median survival of 19.8 vs 29.2 months (p = 0.01). On multivariate analysis, correcting for known poor prognosticators in resectable patients: staging, histologic tumor differentiation and retroperitoneal margin status, diabetes was a significant independent risk factor for increased overall mortality (OR 1.55, 95% CI 1.15–2.07, p = 0.004). Disease-specific mortality was also higher in diabetics vs. non-diabetics with a median survival of 29.87 vs. 21.47 months (OR 1.37 95% CI 1.00–1.89 p = 0.048). Stage specific mortality was also higher among diabetics. Potential etiologies will be discussed. Conclusions: Diabetes worsens disease specific and overall mortality in patients with pancreatic cancer. Diabetes may be a modifiable risk factor and should be considered while prognosticating patients with resectable pancreatic cancer. Further studies are needed to determine whether treatment of diabetes improves outcomes. No significant financial relationships to disclose.